Recruiting
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
NCT07388524· Phase 3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation
NCT07615049· Phase 3· SWOG Cancer Research Network· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940· Phase 3· SWOG Cancer Research Network· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07200830· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Contact: Jamal Misleh, Site 0896
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
NCT06769126· Phase 2· SWOG Cancer Research Network· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
NCT07018869· Phase 3· SWOG Cancer Research Network· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Jamal Misleh, Site 0304
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Active, not recruiting
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT06724237· Phase 3· Eastern Cooperative Oncology Group· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· Phase 2· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Jamal Misleh, Site 0701
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· Phase 3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
NCT06632977· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Source
Contact: Gregroy A Masters (principal investigator)
Active, not recruiting
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243· Phase 3· SWOG Cancer Research Network· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Aaron Mansfield, MD
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Canadian Cancer Trials Group· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Gregory A. Masters (principal investigator)
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Vitamin D for Prostate Endocrine Therapy
NCT05838716· Phase 3· University of Rochester· Source
Contact: Gregory A. Masters (principal investigator)
Active, not recruiting
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
NCT05836584· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT06073431· University of Rochester· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT05976763· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Active, not recruiting
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828· ECOG-ACRIN Cancer Research Group· Source
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory A. Masters (principal investigator)
Showing 50 of 162.